US 2026/0297170 A1 · HUMAN ANTI-FGF2 MONOCLONAL ANTIBODY (MAB), PHARMACEUTICAL COMPOSITION COMPRISING SAME, USE THEREOF AND KIT FOR THE DETECTION OF CANCER IN A BIOLOGICAL SAMPLE COMPRISING SAID MAB

Abstract

The present invention refers to a human anti-FGF2 monoclonal antibody (mAb) comprising the amino acid sequence of the light chain as set in the SEQ ID NO: 1 or 3, and the amino acid sequence of the heavy chain as set in the SEQ ID NO: 2 or 4. Additionally, the present invention refers to a Pharmaceutical composition comprising said mAb and to its use in the production of a medicament to treat cancer. Additionally, the present invention refers to a kit for the detection of FGF2 protein in a biological sample comprising said mAb or a biologically active fragment thereof bound to a detectable fraction and can be used for prognosis or targeting cancer treatment. In addition to the therapeutic use associated with cancers, such as inhibition of angiogenesis, there are potential applications in the control of fibrotic diseases, neutralizing the excessive action of FGF, for example in diseases of intense tissue repair (keloids), and idiopathic fibrosis or secondary fibrosis to chronic inflammatory diseases. In addition to their therapeutic potential, antibodies can be used for immunoscintigraphy, labeled with radioisotopes, for molecular imaging and prediction of fibrosing responses.

Claims10

Dependent claims

Human anti-FGF2 monoclonal antibody (mAb) characterized by the fact that it comprises an antibody heavy chain and an antibody light chain, wherein said chains comprise complementarity determining regions (CDRs) selected from (i) to (ii):

(i) CDR1, CDR2 and CDR3 regions of the light chain with the amino acid sequences of the positions 27-37, positions 55-57 and positions 94-102 of the SEQ ID NO:
1, respectively;
and CDR1, CDR2 and CDR3 regions of the heavy chain with the amino acid sequences of the positions 26-35, positions 53-59 and positions 98-114 of the SEQ ID NO:
2, respectively;
or
(ii) CDR1, CDR2 and CDR3 regions of the light chain with the amino acid sequences of the positions 26-33, positions 51-53 and positions 90-101 of the SEQ ID NO:
3, respectively;
and CDR1, CDR2 and CDR3 regions of the heavy chain with the amino acid sequences of the positions 26-33, positions 51-58 and positions 97-110 of the SEQ ID NO:
4, respectively.

6 more elements

Dependencies are inferred from the claim text.

Human anti-fgf2 monoclonal antibody (mab), pharmaceutical composition comprising same, use thereof and kit for the detection of cancer in a biological sample comprising said mab

Life of this patent

Human anti-fgf2 monoclonal antibody (mab), pharmaceutical composition comprising same, use thereof and kit for the detection of cancer in a biological sample comprising said mab

Life of this patent

Abstract

Claims10